Cantor Fitzgerald Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $166
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $153 to $166.

June 23, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on Sarepta Therapeutics and raises the price target from $153 to $166.
The news of Cantor Fitzgerald maintaining an Overweight rating and raising the price target for Sarepta Therapeutics is positive for the company's stock. This indicates that the analyst believes the stock has potential for further growth and is likely to outperform the market. As a result, this news may lead to an increase in investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100